The partnership began Nov. 1. Vizient customers, which includes 50 percent of acute care providers and 20 percent of ambulatory providers, will receive the drug at a discount. The partnership is slated to last three years.
“Since the launch of dexycu in the first quarter of this year, EyePoint’s dedicated sales team has been making consistent headway in penetrating targeted ambulatory surgical centers to deliver Dexycu to patients who can benefit from the product’s differentiated profile and efficacy,” said Nancy Lurker, president and CEO of EyePoint Pharmaceuticals.
More articles on supply chain:
Medline, HOTB Software Solutions partner to ease accreditation process
ASC software providers collaborate to improve integration, interoperability — 4 things to know
Delaware gastroenterology practice adds Drs. Vineet Gudsoorkar, Shruti Patel — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.